Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiragolumab plus atezolizumab and platinum-pemetrexed versus pembrolizumab and platinum-pemetrexed in previously untreated advanced non-squamous NSCLC
2020-002851-39Phase 2Active
- Sponsor
- Roche
- Start
- Nov 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tiragolumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Roche. Primary endpoint: Investigator-assessed confirmed objective response rate. Started Nov 2020; status: active.
02
Drugs
tiragolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-002851-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002851-39.